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ABSTRACT 
Low back pain is a leading cause of disability, interferes with quality of life and work performance, and is the 
most common reason for medical consultations. Few cases of back pain are due to specific causes; most cases 
are non-specific. The most common presentation is acute back pain and is usually self-limiting, lasting less 
than three months regardless of treatment. Chronic back pain is a more difficult problem, which often has 
strong pathological and psychological overlay like work dissatisfaction, boredom, and a generous 
compensation system contribute to it. Among the diagnoses lumbar spondylosis is blamed. No single 
treatment is superior to others; even surgery is seldom successful at alleviating it. Hence a clinical study was 
conducted on 30 patients with classical sign and symptoms of Katigraha (LBA) with an aim to find out the 
effectiveness of Dvipanchamooladi taila Matra basti (oil enemata of an indigenous compound). The patients 
were randomly divided in to two groups 15 patients in each. Group I (Trial) administered with 
Dvipanchamooladi taila matra basti and Group II (Control) – Ksheerabala taila Matra basti (enemata prepared 
by processing Sida Cordifolia root with milk and sesame oil) for a total period of nine days. The trial drug 
being potentiated by its inherent properties like anti-inflammatory, anodyne etc. exhibited favorable result 
with an effectiveness of 87.30% to reduce the sign and symptom of low back ache & the effect of the trial 
therapy were statistically highly significant with a p-value of > 0.01 in the management of Low back ache. 
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INTRODUCTION
 Low back pain is a common disease manifested 
with pain and stiffness in the lumbar region, which 
hampers the normal activities of the person. With a review 
to Ayurvedic literature, the pathogenesis of this disease is 
not mentioned separately but included under Vata vyadhi 
(disease of locomotion & nervous system), which may be 
co-related to lumbar spondylosis that presents with 
degenerative changes in the lumbar region. Low back ache 
(LBA) affects approximately 60–85% of adults during 
some point in their lives(2). In a large majority of 
individuals, though the symptoms are mild and transient, 
and 90% subsiding within 6 weeks, still for the minority 
with intractable symptoms, the impact on quality of life 
and economic implications are considerable. Chronic low 
back pain, defined as pain, persisting beyond 3 months, 
affects an estimated 15–45% of the population(3). 
“Katigraha” etymologically derived as a disease where the 
patient feels pain and stiffness in the lumbar region, which 
hampers the normal activities of the person. Due to some 
clinico-pathological similarity, it can be co-related to 
Lumbar Spondylosis(4). Varieties of diseases are mentioned 
in modern medical literature which present with pain and 
stiffness in the lumbar region amongst which Lumbar 
Spondylosis accounts 80% incidence in 3rd decades of 
life(3). Hence Katigraha with a co-relation to lumbar 
spondylosis was proposed in the present study. 
Lumbar spondylosis is a degenerative condition 
which affects the lower spine. In a patient with lumbar 
spondylosis, the spine is compromised by a narrowing of 
the space between the vertebrae, causing a variety of 
health problems ranging from back pain to neurological 
issues (5). This condition is usually caused by old age, as the 
spine undergoes changes as people grow older, and many 
of these changes contribute to degeneration of the 
vertebrae.  
Despite the high prevalence of low back pain 
within the general population, the therapeutic options are 
diverse and often inconsistent, resulting in rising costs and 
variability in management throughout the country. For 
complicated cases of Katigraha (lumbar spondylosis) 
Surgery is an option, but the expenditure of surgery may 
not be affordable by all individual. So the need arises to 
search for a better and safer treatment. The “Basti” chikitsa 
(a traditional treatment procedure, where the 
medicaments are infiltrated through anal route) has prime 
importance among Pancha karma (five types of treatment 
for the purification of body from metabolic toxins) because 
of its wide applicability in various conditions & forms. 
Matra basti (enema given in a low dose), the simple form 
of Basti which can be performed very easily even in OPD 
level without any complications. Dvipanchamooladi taila 
has been mentioned by Vangasena Samhita (An ancient 
book written by Vangasena, named as Chikitsa Sara 
samgraha in 1276 A.D.) for Katigraha (6). So the clinical 
study was proposed. 
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Aims & objectives 
 To assess the efficacy of “Matra Basti” with 
Dvipanchamooladi taila in Katigraha. 
Materials and methods 
The study was a single blind clinical trial where 30 
patients were selected by random sampling procedure, 
with a complaint of LBA attending the OPD (Outpatient 
department) & IPD (Inpatient Department) of NKJ. 
Ayurvedic Medical College, Bidar, Karnataka attached to 
Shri Siddharoodha charitable hospital and other associated 
hospital. The selected patients were divided into two 
groups, 15 in each. Initially, history of all patients were 
taken including age, sex, occupation, education, socio 
economic status, history of illness, family history, personal 
history including exercise, habits, diet etc. Physical 
examinations such as coin test, S.L.R (Slow Leg Rising), 
F.N.S (Femoral Nerve Stretching) along with vital statistics 
etc. routine hematological investigations such as Hb% 
(hemoglobin percentage), T.L.C (Total Leucocytes Count), 
D.L.C (Differential Leucocytes Count), E.S.R (Erythrocyte 
Sedimentation Rate), Blood sugar & urine were done to 
diagnose the cases provisionally & to rule out other 
pathology. Finally, X-Ray – Antero posterior & lateral view 
of Lumbo-Sacral spine was taken to diagnose lumbar 
spondylosis. 
Group I (trial group): treated by Dvipanchamooladi taila 
Matra basti (70ml). 
Group II (control group): treated by Ksheerabala taila 
Matra basti (70ml) once daily, for 9 days. Follow up period 
was 27days in total and observations recorded before the 
treatment, on 9th, 18th, and 27th day were assessed, 
statistically analyzed for Matra basti in both groups.  
Inclusion criteria 
Patients were selected between 30-60 yrs of age 
irrespective of sex, presenting with pain and stiffness, with 
positive Coin test, Lumbar Spine Mobility test, SLR test, 
FNS test and diagnosed as Lumbar Spondylosis by X-ray 
radiograph. Patients of spinal diseases like spinal 
tuberculosis, space occupying lesion, prolapsed disc, 
vertebral fracture & Spondylolisthesis, diagnosed case of 
cardiac disease, renal disease & other systemic disorders, 
Were excluded, from the study to avoid complication, drop 
out & biased result. Patient contra- indicated for basti 
karma was also not included in the present study. 
Exclusion criteria 
The indigenous compounds used for the purpose of clinical study, viz. trial drug, (Dwipanchamuladi taila), control 
drug (Ksheerabala taila) and the drug used for pre measure (Karpasastyadi taila) were prepared in the college pharmacy. 
Dvipanchamooladi taila: - Dwipanchamoola taila was prepared by sesame oil after being processed with curd, Kanji (sour 
gruel) & a number of herbal drugs as mentioned in the following table. 
Table 1: Herbal drugs used in Dwipanchamooladi Taila 
Drugs Botanical name Family name Pharmacological Actions 
Bilva Aegle marmelos  Rutaceae Laxative, expectorant, febrifuge 
Agnimantha Premna corymbosa Verbinaceae 
Anti-inflammatory, cardiotonic, expectorant, anti-
bacterial, laxative, anodyne 
Shyonaka Oroxylum indicum Bignoniaceae 
Anti-inflammatory, anodyne, expectorant, diuretic, 
anti-arthritic 
60 assessed for eligibility 
15 allocated to treatment by 
Dwipanchamooladi Matra 
Basti 
15 allocated to treatment by 
Ksheerabala Matra Basti 
 
30 Excluded 
21 not meeting the Inclusion 
criteria 
09 Declined to participate 
15 analyzed BT Vs AT on 
9th, 18th, 27th day 
15 analyzed BT Vs AT on 
9th, 18th, 27th day 
15 Randomized 
AT of allocated treatment 1 
Vs 
AT of Allocated treatment 2 
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Patala Stereospermum colais Bignoniaceae  
Anodyne, appetizer, constipating, diuretic, lithotriptic, 
anti-inflammatory, anti-bacterial 
Gambhari Gmelina arborea Verbinaceae  
Laxative, galactogogue, anthelminthic, anti-
haemorrhoidal 
Kantakari 
Solanum 
xanthocarpum 
Solanaceae  
Diuretic, expectorant, anodyne, laxative, anti-
inflammatory 
Brihati Solanum indicum Solanaceae  Diuretic, expectorant, depurative 
Shalaparni Pseudarthria viscid Fabaceae  
Emmolient, anti-inflammatory, diuretic, cardiotonic, 
febrifuge 
Prushniparni 
Desmodium 
gangeticum 
Fabaceae 
Anti-inflammatory, expectorant, cardiotonic, 
carminative 
Gokshura Tribulus terrestris Xygophyllaceae 
Anti-inflammatory, laxative, lithotriptic, styptic, 
diuretic, expectorant 
Madanaphala  Randia dumatorum Rubiaceae 
Antispasmodic, emetic, anti-inflammatory, 
abortificient, anodyne, antiseptic, antiostalgic 
Karpasasthyadi Tailam: - Karpasastyadi taila was prepared by sesame oil after being processed with a number of herbal 
drugs as mentioned in the following table. 
Table 2: Herbal drugs used in Karpasastyadi Taila  
Drugs Botanical name Family name Pharmacological Actions 
Devadaru Cedrus deodara Pinaceae  Anti-cancerous, anti-inflammatory,  
Bala Sida cordifolia Malvaceae  Aphrodisiac, strengthening, emollient  
Rasna Pluchea lanceolata Zingiberaceae 
Thermogenic, carminative, disinfectant, bronchodilator, anti-
inflammatory, febrifuge 
Kushtha Saussurea lappa Asteraceae Diuretic, disinfectant, expectorant, carminative 
Sarshapa Brassica juncca Brassicaceae Anti-inflammatory, carminative, digestive, anthelmithic 
Nagara Zingiber officinalis Zingiberaceae Emollient, anthelminthic, aphrodisiac 
Shatahwa Anethum sova Apiaceae Cardiotonic, galactogogue, diuretic 
Pippali mula Piper longum Piperaceae Purgative, digestive, emmenogogue 
Karpasa Gossypium berbaceum Malvaceae  Thermogenic, emollient, anti-dysentric, diuretic, anodyne 
Masha Phaseolus mungo Fabaceae Diuretic, galactogogue, appetizer 
Kulatha Dolichos biflorus Fabaceae Thermogenic, ophthalmic, diuretic, emmenogogue 
Chavya Piper chava Araceae Carminative, aphrodisiac, diphoratic 
Sigru Moringa oliefera Moringaceae Carminative, emmenagogue, expectorant, ophthalmic 
Punarnava Boerhaavia diffusa Nictaginaceae Cardiac stimulant, laxative, diuretic, anthelminthic 
Ksheerabala taila: Ksheerabala taila was prepared by sesame oil after being processed with milk and Sida cordifolia 
which possesses the pharmacological actions as aphrodisiac, strengthening and emollient.  
Nadi Swedana : Sudation given to the whole body or a part by boiling the following herbal drugs in a closed container and 
passing the vapour through a pipe. 
Table 3: Herbal drugs used in Nadi Sweda 
Drug Botanical name Family name Pharmacological Actions 
Lashuna Allium sativum Liliaceae Anthelmithic, cardiotonic, aphrodisiac, expectorant, 
febrifuge, emmenagogue, anti-cholestrol, anti-bacterial, 
anti-fungal 
Eranda Ricinus communis Euphorbiaceae Thermogenic, purgative, Anthelmithic, emollient, 
diuretic, galactogogue 
Nirgundi Vitex negundo Verbenaceae Anthelmithic, expectorant, Thermogenic, carminative, 
anodyne, ophthalmic 
Saindhava Rock salt  -  
Arka Calotropis gigantia Asclepiadaceae Expectorant, anthelminthic, rejuvenator, tonic 
Assessment criteria (Subjective and Objective Parameters and Gradation) 
The clinical assessment was made depending upon the improvement of sign & symptom as mentioned below. 
1. Pain 2. Stiffness 3. Restricted Movements. 4. Inflammation 5. Tenderness 6. Coin Test 7. LSM Test 8. SLR Test & 9. FNS 
Test. 
Pain: The intensity of pain was assessed by VAS (Visual Analogue Scale). In VAS a line of 10 mm length which was having 
marking at both ends (0 on the first end & 10 on the other end). Zero denotes no pain & 10 denote most excruciating pain. 
Further grading of pain was done as - 1mm-3mm – Mild, 4mm-6mm – Moderate & 7mm-9mm – Severe pain. The patients 
were advised to mark on the line to show the intensity of pain.  
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The other parameters like stiffness, restricted movements, inflammation, were assessed according to another grading as 
follows. 
Table 4: Symptoms & its Grade points 
Symptoms Score 
0- Nothing specific(G0) 1- Mild (G1) 
2.-Moderate(G2) 3- Severe(G3) 
4 - Most excruciating. 
Stiffness 0 1 2 3 4 
Restricted 
movements 
0 1 2 3 4 
Inflammation 0 1 2 3 4 
Tenderness 0 1 2 3 4 
Coin test : G0 – Easily pick the coin from the ground, G1 – Minimum difficulty to pick the coin, G2 – Moderate difficulty to 
pick the coin, G3 – Severe difficulty to pick the coin, G4 - Unable to pick the coin;  
LSM (Lumbar Spine Mobility) test: G0 – Normal (5cm), G1 – Mild (4-5 cm), G2 – Moderate (2-4 cm), G3 –Severe (0-2 cm), 
G4 - Unable to bend:  
S.L.R. test: G0 – Angle between 700 - 900, G1 – Angle between 500 - 700, G2 – Angle between 300 - 500, G3 – Angle below 
300, G4 - Unable to raise;  
F.N.S. test: G0 – Leg can be stretched & flexed, G1 –Leg can be flexed at the knee but not forwardly stretched, G2 – Leg can 
be flexed with pain but not stretched, G3 – Leg can be flexed & cannot be stretched, G4 – Unable to do any movements.  
 For the purpose of the assessment of result some grade points were used considering the severity of different sign 
and symptoms and Clinical assessment of result was done as: Cure: hundred percent; maximum improvement:75% to 
99%; moderate improvement: 50% to 74%; mild Improvement: 25% to 49% and no improvement: less them 25% 
improvement of the cardinal sign and symptoms, like pain, stiffness, Restricted movements, inflammation, tenderness, 
Coin test, LSM test, SLR test & FNS test.  
For clinical management of Katigraha, all the patients (trial & control) were initially managed by Abhyanga (whole 
body massage) with Karpasasthyadi taila for 35 minutes & Nadi sweda 10 minutes. In the treated group Dvipanchamooladi 
taila70 ml was administered as Matra basti where as Matra basti with Ksheerabala taila 70ml was done in the control 
group. All the patients were provided to take similar dietary regimen. The clinical assessment was done in every 9 days 
interval. The initial findings were compared with the result of progressive 9th day, 18th day and so on of findings. 
Grading/grouping according to the assessment criteria and measurement scale concerned to each item categorically 
differentiated the findings among the patients in the clinical study. And finally the assessment as a whole was presented in 
percent value. 
Observations & Results 
 The patients were analyzed according to various factors like Age, Sex, Religion, Occupation, Prakruti (body 
constituent and temperament), Diet, Habitat, Chronicity, Vyayama shakti (exercise capacity) etc. & details of sign and 
Symptoms. The observations reveled that maximum patients were found in the age group 30- 40 yrs (40%). The incidence 
of Katigraha is more in females as compared to males in the present study. 
Regarding the sign & symptom, initially pain was reported in 93.33% of patients, stiffness in 76.66%, restricted 
movement in 73.33% & inflammation in 60.00%. Whereas on examination it was evidenced that SLR test was +ve in 
90.00% of patients, coin test +ve in 83.33%, LSM test +ve in 73.33% and FNS test +ve in 63.33% of cases. But after the 
treatment and 3rd follow up considerable relief was noticed in all sign and symptom. On 27th day observation pain reduced 
in 88.46 % patients in trial group, whereas in control group reduction of pain was seen in 68 % of cases. Inflammation 
reduced in 86.53 % of trial and 70 % cases in control; Stiffness 82.35% in trial & 65.38 % in control; Restricted Movement 
was reduced in 86 % cases in trial but 64.70 % cases in control. On examination Coin test, SLR, FNS & LSM was seen to be 
negative in 87.75 %, 87.5 %, 88 % & 86 % cases of group I, whereas in group II it was 67.34 %, 74.46 %, 64.58 %, 66.66 % 
respectively. (Table 2&3) 
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Table 5: Signs and symptoms in each group Before treatment 
Incidence Parameters Group I Group II Total % 
Pain 15 13 28 93.33 % 
Inflammation  10 08 18 60.00 % 
Stiffness  11 12 23 76.66 % 
Restricted movements 12 10 22 73.33 % 
Coin Test 13 12 25 83.33 % 
S.L.R Test 12 10 27 90.00 % 
F.N.S.Test 10 09 19 63.33 % 
L.S.M.Test 14 13 22 73.33 % 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Observation on different sign and symptom with percentage of relief 
Sign & Symptom 9th day % 18th day % 27th day % 
Pain T 21.15 % 48.07 % 88.46 % 
C 18 % 42 % 68 % 
Inflammation T 21.15% 51.92 % 86.53 % 
C 16 % 40 % 70 % 
Stiffness 
 
T 17.64 % 49.01% 82.35% 
C 11.53 % 38.46 % 65.38 % 
Restricted movement 
 
T 22 % 54 % 86 % 
C 11.76 % 37.25 % 64.70 % 
Coin test 
 
T 18.36 % 53.06 % 87.75 % 
C 12.24 % 36.73 % 67.34 % 
S.L.R. test 
 
T 12.5% 47.91 % 87.5 % 
C 6.38 % 38.29 % 74.46 % 
F.N.S. test 
 
T 18 % 52 % 88 % 
C 10.41 % 37.5 % 64.58 % 
L.S.M. test 
 
T 18 % 52 % 86 % 
C 12.5 % 37.5 % 66.66 % 
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 In order to present the study in a scientific manner the statistical assessment of the result was done. The mean ± S 
E of each sign and symptom, before treatment had been compared with mean ± S.E. value of after treatment. Paired t-test 
was used for significance and the effectiveness of the trial and control drug was assessed through p-value. (Tables 4-6). 
The statistical analysis signifies that the trail drug was effective in reducing pain, inflammation, stiffness, restricted 
movement and improving the clinical signs as compared to the control group. In the trail group, Matra basti with 
Dvipanchamooladi taila was effective 88.46% on pain, 86.53% on inflammation, 82.35% on stiffness, 86% on restricted 
movement, 87.75% on coin test, 87.5% on SLR, 88% on FNS, 86% on LSM & overall 87.30%. 
Whereas on control group, Ksheerabala taila matra basti was effective 68% on pain, 70% on inflammation,65.38% 
on stiffness, 64.70% on restricted movement, 67.34% on coin test, 74046% on SLR, 64.58% on FNS, 66.66% on LSM & 
overall 68.22%. While comparing the effect of trial verses control it was found that, the trail drug was highly significant to 
reduce pain, LSM & FNS with p-value P<0.01 and significantly effective to reduce other sign symptoms with p-value <0.05. 
As an overall effect trial drug was also significantly high in improving Katigraha (Lumbar Spondylosis) with p-value of 
<0.01 (Table 6). 
Table 7: Effectiveness of trial drug on different sign and symptom 
S.No Symptoms B.T Follow up A.T d.f t value p value Remarks Efficacy% 
Mean±S.E Mean±S.E 
1 Pain 3.46±0.19 9th day 2.93±0.15 14 6.20 P<0.01 H.S 21.15% 
18th day 1.80±0.17 13.22 P<0.01 H.S 48.07% 
27th day 0.40±0.13 20.00 P<0.01 H.S 88.46% 
2 Inflammation 3.46±0.19 9th day 2.73±0.15 6.20 P<0.01 H.S 21.15% 
18th day 1.66±0.15 16.83 P<0.01 H.S 51.92% 
27th day 0.46±0.13 17.74 P<0.01 H.S 86.53% 
3 stiffness 3.4±0.19 9th day 2.8±0.2 4.58 P<0.01 H.S 17.64% 
18th day 1.73±0.18 13.22 P<0.01 H.S 49.01% 
27th day 0.60±0.16 19.34 P<0.01 H.S 82.35% 
4 Restricted 
movement 
3.33±0.21 9th day 2.6±0.16 6.20 P<0.01 H.S 22% 
18th day 1.53±0.13 16.83 P<0.01 H.S 54% 
27th day 0.46±0.13 21.5 P<0.01 H.S 86% 
5 Coin test 3.26±0.20 9th day 2.66±0.15 4.58 P<0.01 H.S 18.36% 
18th day 1.53±0.16 11.30 P<0.01 H.S 53.06% 
27th day 0.4±0.13 14.93 P<0.01 H.S 87.75% 
6 SLR 3.2±0.20 9th day 2.8±0.17 3.05 P<0.01 H.S 12.5% 
18th day 1.66±0.18 9.27 P<0.01 H.S 47.91% 
27th day 0.4±0.13 19.34 P<0.01 H.S 87.5% 
7 FNS 3.33±0.18 9th day 2.73±0.18 4.58 P<0.01 H.S 18% 
18th day 1.6±0.16 11.30 P<0.01 H.S 52% 
27th day 0.4±0.13 19.13 P<0.01 H.S 88% 
8 LSM 3.33±0.18 9th day 2.73±0.15 4.58 P<0.01 H.S 18% 
18th day 1.6±0.16 11.30 P<0.01 H.S 52% 
27th day 0.46±0.13 17.34 P<0.01 H.S 86% 
9 overall 13.13±0.36 9th day 10.93±0.35 11 P<0.01 H.S 16.75% 
18th day 6.4±0.36 29.5 P<0.01 H.S 51.26% 
27th day 1.66±0.21 44.83 P<0.01 H.S 87.30% 
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Table 8: Effectiveness of control drug on different sign and symptom 
Sl.no Symptoms 
B.T 
Follow up 
A.T 
d.f t value p value Remarks Efficacy % 
Mean±S.E Mean±S.E 
1 Pain 3.33±0.21 
9th day 2.73±0.20 
14 
4.58 P<0.01 H.S 18% 
18th day 1.93±0.20 8.57 P<0.01 H.S 42% 
27th day 1.06±0.26 9.93 P<0.01 H.S 68% 
2 Inflammation 3.33±0.18 
9th day 2.8±0.22 4 P<0.01 H.S 16% 
18th day 2±0.21 7.13 P<0.01 H.S 40% 
27th day 1±0.21 12.48 P<0.01 H.S 70% 
3 stiffness 3.46±0.16 
9th day 3.06±0.22 3.05 P<0.01 H.S 11.53% 
18th day 2.13±0.21 8.36 P<0.01 H.S 38.46% 
27th day 1.2±0.27 10.98 P<0.01 H.S 65.38% 
4 
Restricted 
movement 
3.4±0.21 
9th day 0.84±0.21 3.05 P<0.01 H.S 11.76% 
18th day 2.13±0.19 6.14 P<0.01 H.S 37.25% 
27th day 1.2±0.31 9.05 P<0.01 H.S 64.70% 
5 Coin test 3.26±0.20 
9th day 2.86±0.21 3.05 P<0.01 H.S 12.24% 
18th day 2.06±0.20 6.87 P<0.01 H.S 36.73% 
27th day 1.06±0.22 11 P<0.01 H.S 67.34% 
6 SLR 3.13±0.21 
9th day 2.93±0.18 1.87 - N.S 6.38% 
18th day 1.93±0.20 8.29 P<0.01 H.S 38.29% 
27th day 0.8±0.22 18.52 P<0.01 H.S 74.46% 
7 FNS 3.2±0.20 
9th day 2.86±0.19 2.64 P<0.05 S 10.41% 
18th day 2±0.19 8.29 P<0.01 H.S 37.5% 
27th day 1.13±0.21 13.48 P<0.01 H.S 64.58% 
8 LSM 3.2±0.20 
9th day 2.8±0.17 3.05 P<0.01 H.S 12.5% 
18th day 2±0.21 8.29 P<0.01 H.S 37.5% 
27th day 1.06±0.24 16 P<0.01 H.S 66.66% 
9 overall 12.8±0.36 
9th day 11.53±0.32 4.75 P<0.01 H.S 9.89% 
18th day 8±0.44 16.21 P<0.01 H.S 37.5% 
27th day 4.06±0.49 27.66 P<0.01 H.S 68.22% 
Table 9: Effectiveness of Trial Vs control drug on different sign and symptom 
S.No Symptoms Follow up 
Trial Control 
d.f t value p value Remarks 
Mean±S.E Mean±S.E 
1 Pain 
9th day 0.73±0.13 0.60±0.13 
28 
0.75 - N.S 
18th day 1.66±0.12 1.40±0.16 1.29 - N.S 
27th day 3.06±0.15 2.26±0.22 2.91 P<0.01 H.S 
2 Inflammation 
9th day 0.73±0.11 0.53±0.13 1.12 - N.S 
18th day 1.80±0.10 1.33±0.18 2.16 P<0.05 S 
27th day 3±0.16 2.33±0.18 2.64 P<0.05 S 
3 Stiffness 
9th day 0.60±0.13 0.40±0.13 1.08 - N.S 
18th day 1.66±0.12 1.33±0.15 1.64 - N.S 
27th day 2.8±0.14 2.26±0.20 2.11 P<0.05 S 
4 Restricted movement 
9th day 0.73±0.11 0.40±0.13 1.88 - N.S 
18th day 1.8±0.10 1.26±0.20 2.29 P<0.05 S 
27th day 2.86±0.13 2.20±0.24 2.40 P<0.05 S 
5 Coin test 
9th day 0.6±0.13 0.4±0.13 1.08 - N.S 
18th day 1.73±0.15 1.2±0.17 2.29 P<0.05 S 
27th day 2.86±0.19 2.2±0.2 2.40 P<0.05 S 
6 SLR 
9th day 0.4±0.13 0.2±0.10 1.18 - N.S 
18th day 1.53±0.16 1.2±0.14 1.51 - N.S 
27th day 2.8±0.14 2.33±0.12 2.43 P<0.05 S 
7 FNS 
9th day 0.6±0.13 0.33±0.12 1.46 - N.S 
18th day 1.73±0.15 1.2±0.14 2.52 P<0.05 S 
27th day 2.93±0.15 2.06±0.15 3.99 P<0.01 H.S 
8 LSM 
9th day 0.6±0.13 0.4±0.13 1.08 - N.S 
18th day 1.73±0.15 1.2±0.14 2.52 P<0.05 S 
27th day 2.86±0.16 2.13±0.13 3.45 P<0.01 H.S 
9 Overall 9th day 2.2±0.2 1.26±0.26 2.8 P<0.05 S 
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18th day 6.73±0.22 4.8±0.29 5.17 P<0.01 H.S 
27th day 11.46±0.25 8.73±0.31 6.72 P<0.01 H.S 
DISCUSSION
Katigraha is a pain dominant disorder, seems to 
be apparently non-serious but cripples the patient if not 
treated properly, and may lead to catastrophic 
complication. The pathogenesis according to Ayurveda is 
either by Dhatukshaya (depletion of tissue elements), 
Margaavarana (obstruction of nourishing channels) or due 
to Abhighata (trauma) (7,8). In turn improper nourishment 
of Rasadi dhatus (nutritive part of metabolized food), leads 
into Kshaya avastha (depletion of tissue element), may be 
correlated to degenerative changes. Lumbar spondylosis is 
pain in lumbar region which begins as a result of 
degenerative changes. 
In the present study maximum patients were 
registered in the age group of 30-40 years (40%). 
According to Sushruta these age groups are in middle age 
group where gradual decline of vitality of body and 
degenerative process (Shrira bala and Dhatus) starts, this 
provokes Vata (degenerative changes in spine & nervous 
system - Su.Su.35/35). Modern texts also say that, this is 
the beginning of the ageing process and degenerative 
changes in spine develop at this age. 
Regarding Occupation, Maximum patients were 
house wife (46.67 %). 16.67% patients were belonging to 
labors. There was history of heavy weight lifting; standing 
for long time etc and 36.67% were belonging to serviced 
category. 
The trail drug Dvipanchamooladi taila contains 
Dashmoola, Kanjika, Dadhi, Madanaphala and Tila taila 
which are Vata-kapha shamaka (alleviated degeneration 
and improves vitality), anti-inflammatory & analgesic. The 
photochemical screening indicates the presence of the 
phyto constituents such as Vitamins, Alkaloids, Saponins, 
Flavonids & Steroid have analgesic, anti inflammatory 
properties which explains the relief of pain in Katigraha. 
 It is proven fact that serum protein and fatty acid 
levels increase after Basti Karma. These are necessary for 
nourishment of the nervous tissue (9). Also Basti acts on the 
natural bacterial flora of the intestines which is important 
for the synthesis of Vit. B6, B12. Bastichikitsa decreases the 
ketoacid and pyruvic acid levels, due to which Vit. B 
synthesis increases. This Vit. B restricts the demyelination 
process of the nerves and helps in regeneration. The 
potency of Basti dravyas (ingredients of enema) spreads 
through A.N.S (Autonomic nervous system) and expels out 
vitiated Doshas (metabolic toxins) from the body. This 
signifies its action on the nervous system(10) Regarding the 
acceptability of the trial drug it may be declared that the 
Dvipanchamooladi taila is a good medicine for Katigraha 
due to its pain relieving and anti inflammatory properties. 
Its use along with the procedure Matra basti found 
remedial in almost all the cases in the study though it did 
not give 100 % results. 
CONCLUSION 
Katigraha is a common disease & has complexity 
of pathology which makes the disease critical. Hence, the 
remedial field is not easier. After seeing the effect on all the 
patients, it is established that Dvipanchamooladi taila 
Matra basti efficiently reduces pain, stiffness, tenderness 
and restricted movements etc. It is observed that the 
therapy along with this drug acted mainly on pain in 
comparison to other parameters. The average retention 
time of Matra basti was noted around 9-10 hours. During 
the procedure, no complication had been noticed. 
However, It may not be claimed that, the work is of high 
proficiency in the field of research, but may shed a beam of 
ray in future study regarding the disease and its treatment. 
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